Valeant Pharmaceuticals International (VRX) shares have surged in trading today following a rating upgrade from Morgan Stanley. Morgan Stanley analyst David Risinger upgraded the stock to Overweight from Equal Weight with a price target of $42 (45% upside) citing the expectation of successful renegotiation of debt covenants, improved cash flow from operations and the reduction in debt.